The effects of the proliferator-activated receptor gamma (PPARy) peroxisome agonist rosiglitazone on airway hyperreactivity.

Trial Profile

The effects of the proliferator-activated receptor gamma (PPARy) peroxisome agonist rosiglitazone on airway hyperreactivity.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2011

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Sep 2011 Actual initiation date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Primary endpoint identified as Methacholine provocation concentration as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top